http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
-
Gilead Sciences (GILD) and MacroGenics (MGNX) Announce Oncology Collaboration to Develop Bispecific Antibodies
-
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
-
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022
-
Gilead Sciences (GILD) Announces U.S. FDA Accepts for Priority Review sBLA for Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
-
Gilead Sciences' (GILD) Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
-
Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
-
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
-
Gilead Sciences (GILD) Completes Acquisition of MiroBio
-
Gilead Sciences Completes Acquisition of MiroBio
-
Gilead Sciences (GILD) Announces Kite's CAR T-cell Therapy Yescarta First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and HGBL
-
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
-
Gilead Sciences (GILD) Reports Positive CHMP Opinion for Treatment of Pediatric Patients with Veklury
-
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
-
Gilead Sciences (GILD) Announces WHO's Expanded Recommendation for Veklury for Patients With Severe COVID-19
-
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
-
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
-
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
-
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
-
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
Gilead Sciences (GILD) Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types
-
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
-
Gilead Sciences (GILD) Granted Approval of Sunlenca in EU
-
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
-
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
-
Gilead Sciences (GILD) Acquires Remaining Worldwide Rights of Trodelvy
-
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
-
Gilead Sciences (GILD) Announces Trodelvy Significantly Improves OS in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
-
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
-
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
-
Gilead Sciences (GILD) Acquires MiroBio
-
Gilead Sciences to Acquire MiroBio
-
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
-
AlloVir Announces $126.6 Million Registered Direct Offering
-
Gilead Sciences (GILD) Announces Kite’s CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia
-
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
-
Gilead Sciences (GILD) Receives Positive CHMP Opinion Recommending Veklury Receive Full Marketing Authorization
-
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
-
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
-
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
-
Gilead Sciences (GILD) Enters Procurement Agreement with the European Commission for Veklury
-
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
-
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
-
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
-
Gilead Sciences (GILD) Granted EU Approval for Yescarta for Treatment of Relapsed or Refractory Follicular Lymphoma
-
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
-
Gilead Sciences (GILD) Resubmits NDA to FDA for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
-
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
